Save after changing Favorites. Use Share Link when you want the same list on another device.
Your link (Favorites):
All Favorites
#
Name
Description
Category
Type
Source
Website
TEN
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Aclidiniumbromid, ATC R03AL05
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TEN
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TEN
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Meropenem, ATC J01DH02
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TEN
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Fluticason, ATC R03AK11
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TEN
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21
ted.europa.eu
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TEN
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tamsulosin + Solifenacin, ATC G04CA53 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Aclidiniumbromid, ATC R03BB05 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Dupilumab, ATC D11AH05 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pimecrolimus, ATC D11AH02 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon beta-1a, ATC L03AB13 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Fertigarzneimittel SMOFkabiven, ATC B05BA10 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Interferon beta-1a (ausschl. z. intramuskulären Injektion), ATC L03AB07 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol + Aclidiniumbromid, ATC R03AL05 für die Zeit 01.05.2025 - 30.04.2027
Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-03
ted.europa.eu
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TEN
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens
ted.europa.eu
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
GRA
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
grants.gov
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA...
GrantCash GrantUnited StatesOpen
AmountAward ceiling: $1,500,000
DeadlineMar 5, 2027
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
GRA
Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
grants.gov
The purpose of this Notice of Funding Opportunity (NOFO) is to support investigators who have the interest and capability to join efforts for the disc...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 5, 2027
The purpose of this Notice of Funding Opportunity (NOFO) is to support investigators who have the interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds.Through this NOFO, NIH wishes to stimulate research in:Discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) andDiscovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms.Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.
GRA
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
grants.gov
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineMar 6, 2027
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
GRA
Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
grants.gov
The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biol...
GrantMixedUnited StatesOpen
AmountAward ceiling: $500,000
DeadlineMar 6, 2027
The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators...
TEN
Lithuania – Engineering design services – (PU-12091/24) Susisiekimo komunikacijų projektavimo ir projekto vykdymo priežiūros paslaugos
Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
37677
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
37691
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-VerfahrensBuyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-03-05
37692
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and sub...
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
37693
Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)The purpose of this Notice of Funding Opportunity (NOFO) is to support investigators who have the interest and capability to join...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The purpose of this Notice of Funding Opportunity (NOFO) is to support investigators who have the interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds.Through this NOFO, NIH wishes to stimulate research in:Discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Eye Institute (NEI), and/or National Institute on Aging (NIA) andDiscovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms.Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.
37694
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and sub...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
37695
Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the trans...
The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.
37696
Lithuania – Engineering design services – (PU-12091/24) Susisiekimo komunikacijų projektavimo ir projekto vykdymo priežiūros paslaugosBuyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-03-07
Tender
Procurement Contract
Lithuania
Not provided on the source page. Please check the official source.
